AAAAAA
Results: 101-125/146
Authors:
MARKMAN M
FRANCIS P
ROWINSKY E
HAKES T
REICHMAN B
JONES W
LEWIS JL
RUBIN S
CURTIN J
BARAKAT R
PHILLIPS M
HOSKINS W
Citation: M. Markman et al., RATIONALE FOR THE INTRAPERITONEAL ADMINISTRATION OF PACLITAXEL (TAXOL(R)) IN THE TREATMENT OF OVARIAN-CANCER, International journal of gynecological cancer, 4, 1994, pp. 19-22
Authors:
MARKMAN M
Citation: M. Markman, REALISTIC GOALS OF CANCER-THERAPY - EFFECTIVE AND HUMANE CARE, Cleveland Clinic journal of medicine, 61(6), 1994, pp. 468-472
Authors:
MARKMAN M
Citation: M. Markman, COMMON COMPLICATIONS AND EMERGENCIES ASSOCIATED WITH CANCER AND ITS THERAPY, Cleveland Clinic journal of medicine, 61(2), 1994, pp. 105-114
Authors:
MARKMAN M
Citation: M. Markman, OVARIAN-CANCER UPDATE - MANAGEMENT CHALLENGES AND ADVANCES, Cleveland Clinic journal of medicine, 61(1), 1994, pp. 51-58
Authors:
MARKMAN M
Citation: M. Markman, WHEN REGULATORY REQUIREMENTS CONFLICT WITH ETHICAL STUDY DESIGN - THECASE OF ORAL ONDANSETRON, Cancer investigation, 12(6), 1994, pp. 654-656
Authors:
RUSCH V
SALTZ L
VENKATRAMAN E
GINSBERG R
MCCORMACK P
BURT M
MARKMAN M
KELSEN D
Citation: V. Rusch et al., A PHASE-II TRIAL OF PLEURECTOMY DECORTICATION FOLLOWED BY INTRAPLEURAL AND SYSTEMIC CHEMOTHERAPY FOR MALIGNANT PLEURAL MESOTHELIOMA/, Journal of clinical oncology, 12(6), 1994, pp. 1156-1163
Authors:
MARKMAN M
Citation: M. Markman, 25TH MEETING OF THE SOCIETY-OF-GYNECOLOGIC-ONCOLOGISTS - ORLANDO, FLORIDA, FEBRUARY 1994, Journal of cancer research and clinical oncology, 120(9), 1994, pp. 562-563
Authors:
MARKMAN M
Citation: M. Markman, CANCER SURVIVAL AND THE MIND, Journal of cancer research and clinical oncology, 120(8), 1994, pp. 443-444
Authors:
MARKMAN M
Citation: M. Markman, 35TH ANNUAL-MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY, ST-LOUIS, MISSOURI, DECEMBER 1993, Journal of cancer research and clinical oncology, 120(7), 1994, pp. 437-438
Authors:
MARKMAN M
Citation: M. Markman, SCREENING FOR OVARIAN-CANCER - IS IT APPROPRIATE, Journal of cancer research and clinical oncology, 120(5), 1994, pp. 257-258
Authors:
MARKMAN M
Citation: M. Markman, PHARMACEUTICAL ADVERTISING AND THE COST OF MEDICAL-CARE, Journal of cancer research and clinical oncology, 120(4), 1994, pp. 191-192
Authors:
MARKMAN M
Citation: M. Markman, 4TH BIENNIAL MEETING OF THE INTERNATIONAL-GYNECOLOGIC-CANCER-SOCIETY,STOCKHOLM 1993, Journal of cancer research and clinical oncology, 120(4), 1994, pp. 248-249
Authors:
MARKMAN M
Citation: M. Markman, REVISITING THE DEBATE - THE USE OF NEW AGENTS IN PREVIOUSLY UNTREATEDPATIENTS WITH SMALL-CELL LUNG-CANCER - QUALITY VERSUS DURATION OF SURVIVAL, Journal of cancer research and clinical oncology, 120(12), 1994, pp. 693-694
Authors:
MARKMAN M
Citation: M. Markman, 85TH ANNUAL-MEETING OF THE AMERICAN-ASSOCIATION-FOR-CANCER-RESEARCH -SAN-FRANCISCO, CALIFORNIA, APRIL-1994, Journal of cancer research and clinical oncology, 120(12), 1994, pp. 743-744
Authors:
MARKMAN M
Citation: M. Markman, 30TH ANNUAL-MEETING OF THE AMERICAN-SOCIETY-OF-CLINICAL-ONCOLOGY - DALLAS, TEXAS, MAY-1994, Journal of cancer research and clinical oncology, 120(12), 1994, pp. 745-746
Authors:
MARKMAN M
Citation: M. Markman, A PROPOSAL FOR DECIDING WHEN TO PROPHYLACTICALLY ADMINISTER BONE-MARROW (GRANULOCYTE) STIMULATORY FACTORS TO PATIENTS RECEIVING CYTOTOXIC CHEMOTHERAPY, Journal of cancer research and clinical oncology, 120(11), 1994, pp. 629-630
Authors:
MARKMAN M
Citation: M. Markman, THE DIFFICULTY DEFINING BENEFIT OF NEW ANTINEOPLASTIC STRATEGIES, Journal of cancer research and clinical oncology, 120(10), 1994, pp. 569-570
Authors:
MARKMAN M
Citation: M. Markman, INTRODUCTION - TREATMENT OF MALIGNANCIES POORLY RESPONSIVE TO CURRENTLY AVAILABLE ANTINEOPLASTIC THERAPY, Seminars in oncology, 21(4), 1994, pp. 1-2
Authors:
MARKMAN M
Citation: M. Markman, INTRAPERITONEAL CISPLATIN AND CARBOPLATIN IN THE MANAGEMENT OF OVARIAN-CANCER, Seminars in oncology, 21(2), 1994, pp. 17-19
Authors:
FENNELLY D
VAHDAT L
SCHNEIDER J
REICH L
HAMILTON N
HAKES T
RAPTIS G
WASSERHEIT C
KRITZ A
GULATI S
MARKMAN M
HOSKINS W
NORTON L
CROWN J
Citation: D. Fennelly et al., HIGH-INTENSITY CHEMOTHERAPY WITH PERIPHERAL-BLOOD PROGENITOR-CELL SUPPORT, Seminars in oncology, 21(2), 1994, pp. 21-25
Authors:
MARKMAN M
Citation: M. Markman, FOLLOW-UP OF THE ASYMPTOMATIC PATIENT WITH OVARIAN-CANCER, Gynecologic oncology, 55(3), 1994, pp. 134-137
Authors:
MARKMAN M
Citation: M. Markman, RESETTING THE CA-125 RANGE FOR A COMPLETE RESPONSE TO CHEMOTHERAPY - WHY, Gynecologic oncology, 53(3), 1994, pp. 281-282
Authors:
MARKMAN M
KENNEDY A
WEBSTER K
KULP B
PETERSON G
BELINSON J
Citation: M. Markman et al., PACLITAXEL (T) GIVEN AS A 3-HOUR (HR) INFUSION ALONG WITH CISPLATIN (C) IN PATIENTS (PTS) WITH GYNECOLOGIC CANCERS, Clinical research, 42(2), 1994, pp. 10000342-10000342
Authors:
FENNELLY D
WASSERHEIT C
SCHNEIDER J
HAKES T
REICH L
CURTIN J
YAO TJ
MARKMAN M
NORTON L
CROWN J
Citation: D. Fennelly et al., SIMULTANEOUS DOSE-ESCALATION AND SCHEDULE INTENSIFICATION OF CARBOPLATIN-BASED CHEMOTHERAPY USING PERIPHERAL-BLOOD PROGENITOR CELLS AND FILGRASTIM - A PHASE-I TRIAL, Cancer research, 54(23), 1994, pp. 6137-6142
Authors:
MARKMAN M
Citation: M. Markman, INTRAPERITONEAL THERAPY FOR TREATMENT OF MALIGNANT DISEASE PRINCIPALLY CONFINED TO THE PERITONEAL-CAVITY, Critical reviews in oncology/hematology, 14(1), 1993, pp. 15-28